Ascendis Pharma A/S Net Profit Margin Growth & History (ASND)
Ascendis Pharma A/S's net profit margin was −31.67% for fiscal 2025.
View full Ascendis Pharma A/S company overviewAscendis Pharma A/S annual net profit margin history
| Fiscal year | Period ended | Net profit margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −31.67% | +72.31 pp |
| 2024 | 2024-12-31 | −103.97% | +76.54 pp |
| 2023 | 2023-12-31 | −180.51% | +959.12 pp |
| 2022 | 2022-12-31 | −1,139.63% | +3791.93 pp |
| 2021 | 2021-12-31 | −4,931.56% | +1093.97 pp |
| 2020 | 2020-12-31 | −6,025.53% | −4395.50 pp |
| 2019 | 2019-12-31 | −1,630.03% | −400.49 pp |
| 2018 | 2018-12-31 | −1,229.53% | +6868.31 pp |
| 2017 | 2017-12-31 | −8,097.84% | −6610.54 pp |
| 2016 | 2016-12-31 | −1,487.30% | −1081.76 pp |
| 2015 | 2015-12-31 | −405.54% | — |
Ascendis Pharma A/S quarterly net profit margin
| Fiscal quarter | Period ended | Net profit margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 61.00% | +85.59 pp |
| Q1 2026 | 2026-03-31 | 255.21% | +348.94 pp |
| Q4 2025 | 2025-12-31 | −13.56% | +8.56 pp |
| Q3 2025 | 2025-09-30 | −28.55% | +142.98 pp |
| Q2 2025 | 2025-06-30 | −24.58% | +279.27 pp |
| Q1 2025 | 2025-03-31 | −93.73% | +42.91 pp |
| Q4 2024 | 2024-12-31 | −22.12% | +40.97 pp |
| Q3 2024 | 2024-09-30 | −171.52% | +166.20 pp |
| Q2 2024 | 2024-06-30 | −303.85% | −47.62 pp |
| Q1 2024 | 2024-03-31 | −136.65% | +193.56 pp |
| Q4 2023 | 2023-12-31 | −63.09% | +842.84 pp |
| Q3 2023 | 2023-09-30 | −337.73% | +767.28 pp |
| Q2 2023 | 2023-06-30 | −256.23% | +1063.89 pp |
| Q1 2023 | 2023-03-31 | −330.21% | +1507.78 pp |
| Q4 2022 | 2022-12-31 | −905.93% | +1259.95 pp |
| Q3 2022 | 2022-09-30 | −1,105.00% | +6114.04 pp |
| Q2 2022 | 2022-06-30 | −1,320.11% | +11828.03 pp |
| Q1 2022 | 2022-03-31 | −1,837.99% | +6579.17 pp |
| Q4 2021 | 2021-12-31 | −2,165.88% | +23808.89 pp |
| Q3 2021 | 2021-09-30 | −7,219.05% | −2803.34 pp |
| Q2 2021 | 2021-06-30 | −13,148.14% | −6537.28 pp |
| Q1 2021 | 2021-03-31 | −8,417.16% | −5571.45 pp |
| Q4 2020 | 2020-12-31 | −25,974.77% | −22769.26 pp |
| Q3 2020 | 2020-09-30 | −4,415.71% | −3296.09 pp |
| Q2 2020 | 2020-06-30 | −6,610.86% | −4776.42 pp |
| Q1 2020 | 2020-03-31 | −2,845.71% | −1855.00 pp |
| Q4 2019 | 2019-12-31 | −3,205.50% | −2901.39 pp |
| Q3 2019 | 2019-09-30 | −1,119.62% | +168715.38 pp |
| Q2 2019 | 2019-06-30 | −1,834.44% | +124704.44 pp |
| Q1 2019 | 2019-03-31 | −990.71% | +146777.15 pp |
| Q4 2018 | 2018-12-31 | −304.12% | +11901.24 pp |
| Q3 2018 | 2018-09-30 | −169,835.00% | −162029.24 pp |
| Q2 2018 | 2018-06-30 | −126,538.89% | −119623.12 pp |
| Q1 2018 | 2018-03-31 | −147,767.86% | −141010.06 pp |
| Q4 2017 | 2017-12-31 | −12,205.36% | — |
| Q3 2017 | 2017-09-30 | −7,805.76% | — |
| Q2 2017 | 2017-06-30 | −6,915.77% | — |
| Q1 2017 | 2017-03-31 | −6,757.80% | — |
Ascendis Pharma A/S net profit margin trends
Over the last five fiscal years, Ascendis Pharma A/S's net profit margin increased from −6,025.53% to −31.67%, a change of +5993.86 percentage points. The latest reported quarter, Q2 2026, shows 61.00%.
What net profit margin means
Net profit margin measures the percentage of revenue remaining as net income after operating costs, interest, taxes, and other expenses. It shows how much bottom-line profit or loss a company generates from each dollar of revenue.
How net profit margin is calculated
TickerStat calculates net profit margin as SEC-reported net income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Ascendis Pharma A/S source filings ↗